AG真人官方

Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of Directors

LEXINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the 鈥淐ompany鈥� or 鈥淩apid Micro鈥�), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to welcome Dr. Dafni Bika to the Company鈥檚 Board of Directors (the 鈥淏oard鈥�).

鈥淲e are extremely pleased to welcome Dr. Bika to our Board of Directors,鈥� said Robert Spignesi, President and Chief Executive Officer. 鈥淒afni has more than 25 years of leadership experience in pharmaceutical development and manufacturing science and technology. She brings a wealth of knowledge and strategic insight that will contribute to our growth as we continue to establish the Growth Direct platform as the industry standard for automating pharmaceutical QC testing. We are excited to add her expertise to our Board.鈥�

Dr. Bika currently serves as Senior Vice President and Global Head of Pharmaceutical Technology and Development at AstraZeneca plc, where she leads a global team of scientists and engineers in advancing synthetic molecules into approved medicines. Prior to joining AstraZeneca, Dr. Bika held senior executive roles at Bristol-Myers Squibb Company, overseeing Manufacturing Technology, Packaging Technology and Device Operations as well as Global Drug Product Manufacturing Science and Technology. Earlier in her career, she served as the Director of Global Pharmaceutical Commercialization at Merck & Co., Inc.

鈥淚 am honored to join the Board at Rapid Micro Biosystems,鈥� said Dr. Bika. 鈥淚 look forward to collaborating with the management team and my fellow Board members as we advance the Company鈥檚 mission to modernize pharmaceutical quality control and manufacturing with the Growth Direct platform.鈥�

Dr. Bika holds a Ph.D. in Materials Science and Engineering from the University of Pennsylvania, a Master of Science in Materials Science and Engineering from the University of Rochester, NY, and a Diploma in Chemical Engineering from the National Technical University of Athens (Greece).

About Rapid Micro Biosystems听

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company鈥檚 flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (鈥淢QC鈥�) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit听听or follow the Company on X (formerly known as Twitter) at听听or on听.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company's mission to modernize pharmaceutical manufacturing with its Growth Direct technology. In some cases, you can identify forward-looking statements by terminology such as 鈥渙utlook,鈥� 鈥渁im,鈥� 鈥渁nticipate,鈥� 鈥渁ssume,鈥� 鈥渂elieve,鈥� 鈥渃ontemplate,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渄ue,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥済oal,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渙bjective,鈥� 鈥減lan,鈥� 鈥減redict,鈥� 鈥減otential,鈥� 鈥減ositioned,鈥� 鈥渟eek,鈥� 鈥渟hould,鈥� 鈥渢arget,鈥� 鈥渨ill,鈥� 鈥渨ould鈥� and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to risks related to, the Company's ability to achieve positive cash flow without requiring additional financing; the Company's ability to achieve its business objectives; the Company's significant losses since inception; the Company鈥檚 ability to meet its publicly announced guidance and other expectations about its business and operations; the Company鈥檚 limited experience in marketing and sales and the effectiveness of its sales processes; the Company鈥檚 need to develop new products and adapt to technological changes; the Company鈥檚 ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company鈥檚 ability to maintain its manufacturing facility; the Company's ability to improve the gross margins of its products and services; risks related to third-parties; the Company鈥檚 ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; risks associated with macroeconomic events and uncertainty, including with respect to tariff and trade policy in the U.S. and abroad, as well as activity in the Company's industry and in the general economy; and the other important factors outlined under the caption 鈥淩isk Factors鈥� in the Company鈥檚 Quarterly Report on Form 10-Q filed with the SEC, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

Rapid Micro Biosystems Investor Contact:听
Michael Beaulieu, CFA听
Vice President, Investor Relations and Corporate Communications听
[email protected]听

Rapid Micro Biosystems Media Contact:听